Drug combination with radiation for recurrent cervical cancer
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests a combination of two drugs (nimotuzumab and tislelizumab) alongside radiation therapy for people whose cervical cancer has returned or spread to a few other places. The goal is to see if this approach can help control the cancer better and improve survival.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have cervical cancer that has returned or spread to no more than 5 spots in the body.
- You are able to receive radiation therapy.
- You have at least one tumor that can be measured on scans.
- You are expected to live at least 3 more months.
- Your blood counts and liver/kidney function are within acceptable levels.
- Your heart pumps well enough (at least 50% ejection fraction).
- If you can become pregnant, you agree to use birth control during and after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests adding a targeted drug called nimotuzumab to the standard chemoradiotherapy for cervical cancer, followed by ongoing maintenance treatment. It aims to see if this combination helps control the cancer better than chemoradiotherapy alone.
This trial tests a combination of three drugs—camrelizumab (an immunotherapy that helps your immune system fight cancer), famitinib (a targeted therapy that blocks blood vessel growth to tumors), and standard chemotherapy—for cervical cancer that has come back or spread and cannot be removed with surgery or radiation. The goal is to see if this combination is safe and effective.
This trial tests whether adding tislelizumab to standard chemotherapy and radiation works better as first treatment for stage IIIC2 cervical cancer. It aims to improve how well the cancer responds and controls the disease.
This trial tests whether adding two immunotherapy drugs (iparomlimab and tuvonralimab) to standard chemoradiation can help people with cervical cancer that has returned or spread to a few new places. The goal is to see if this combination improves outcomes for those whose cancer is no longer responding to initial treatment.
This study tests whether combining immunotherapy with chemotherapy, followed by radiation plus immunotherapy, can work better than standard treatment for cervical cancer. It aims to help patients whose cancer has not spread yet.
This study tests a new drug called zimberelimab, which helps the immune system fight cancer, after standard radiation and chemotherapy for cervical cancer. It might improve the chances of keeping the cancer from coming back.
Hear when a new Cervical Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.